Log In to Order Resources
| Register >
Shopping Cart
In acute ischemic stroke Take action with activase (alteplase) The only evidence-based drug treatment for acute ischemic stroke
Telestroke Discover how telestroke allows for specialized stroke care to underserved area.

AIS Virtual Patient

Virtually assess potential acute ischemic stroke patient scenarios

Test your stroke diagnostic skills today!

Go Now Go Now

Receive a certificate* upon completion of the AIS Virtual Patient Program!

*This certificate does not satisfy requirements for Continuing Education credits

1 2 3 4

Education and Training


Free access to educational materials and training on acute ischemic stroke and Activase for your stroke center. 

Learn More

Dosing and Administration for Acute Ischemic Stroke

Dosing Vial

View videos and instructions for the appropriate dosing and administration of Activase for acute ischemic stroke.

View Now

Register for Updates

Educational Resources

Receive updates and gain free access to order educational resources.

Register Now

Already registered?
Log In >

Exclamation Point

Before you start exploring, please read the Important Safety Information.

Download Full
Prescribing Information

Acute Ischemic Stroke Indication

Activase is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS in the full prescribing information).

Acute Massive Pulmonary Embolism Indication

Activase is indicated in the management of acute massive pulmonary embolism (AMPE) in adults: (1) for the lysis of acute pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments of the lungs; (2) for the lysis of pulmonary emboli accompanied by unstable hemodynamics, eg, failure to maintain blood pressure without supportive measures. The diagnosis should be confirmed by objective means, such as pulmonary angiography or noninvasive procedures such as lung scanning.

Acute Myocardial Infarction Indication

Activase (alteplase) is indicated for use in the management of acute myocardial infarction in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms.

Important Safety Information


Acute Ischemic Stroke (AIS):

Pulmonary Embolism (PE):

Acute Myocardial Infarction (AMI):


The risks of Activase therapy for all approved indications may be increased and should be weighed against the anticipated benefits in certain conditions [See WARNINGS in the full prescribing information].

Acute Ischemic Stroke (AIS):

Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended [See WARNINGS in the full prescribing information].

Pulmonary Embolism (PE):

Acute Myocardial Infarction (AMI):


Orolingual angioedema has been observed in postmarketing experience in patients treated with Activase for AIS. Patients should be monitored during and for several hours after infusion for signs of orolingual angioedema.


The most common complication during Activase therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, Activase therapy should be discontinued immediately, along with any concomitant therapy with heparin. Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

Activase for Acute Ischemic Stroke
Stroke Centers and Telestroke
Resource Center
Patients and Families

    You are now leaving Activase.com

    The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites it does not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

    Continue Return to Site
    <% string shareurl="../home/index.jsp" session.removeattribute("shareend"); if(shareurl.equals("")) { ; } %> Close

    Thank You! An Email Has Been Sent to:

    <% string emails="request.getSession().getAttribute("sentTo").toString();" ; if(request.getsession().getattribute("sentto") !="null)" %> <% emails %>



    Please Log In or Register Now

    Registered User Login



    Forgot your password?
    Click here

    Log In

    Not a Registered User?

    Register now to order free resources and receive updates.

    Register Now <%if(isshoppingcart && (cart.itemsincart() !="0))" {%>
    Items in your cart
    <% cart.itemsincart() %>
    <%} %>

    Thank You for Registering!



    Browser Advisory

    We recommend you use Internet Explorer 9 or higher, or the most current version of Firefox, Safari, or Google Chrome. If you have a previous version of one of these browsers you can download a free copy of the latest version from Microsoft, Firefox, Apple, or Google, or contact your technical support for assistance.